SKIN The Journal of Cutaneous Medicine

Howard Sofen, Stephen Tyring, Sandra Marchese Johnson, Scott Guenthner, Patrick Shannon, Philip M. Brown, Katherine Tillman, Nancy Fitzgerald, Brandon Kirsch, Anna Tallman

Page s235

PDF

Time to Onset of a Minimal Clinically Important Difference in DLQI with Guselkumab Treatment in VOYAGE 1

Nastaran Abbarin, Kim Papp, Richard Langley, David Adam, Vincent Ho, Laura Park-Wyllie, Megan Miller, Yin You, Ya-Wen Yang, Melinda Gooderham

Page s236

PDF

PASI Improvement in the First 12 weeks from the Phase 3 VOYAGE 1, VOYAGE 2, ORION and ECLIPSE Guselkumab Clinical Trials

Nastaran Abbarin, Kim Papp, Ronald Vender, Richard Langley, Vincent Ho, Laura Park-Wyllie, Megan Miller, Yin You, Ya-Wen Yang

Page s237

PDF

Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Efficacy by Baseline Body Surface Area (BSA) Involvement and Baseline Psoriasis Area and Severity Index (PASI)

Jeffrey M. Sobell, Boni Elewski, Subhashis Banerjee, Eugene Balagula, Thomas Scharnitz, Victoria Berger, Kim Hoyt, Paul Yamauchi, Miriam Bettencourt, Michael C. Cameron, Mark Lebwohl

Page s238

PDF

Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Absolute PASI Outcomes Over 52 Weeks in the Phase 3 POETYK PSO-1 Trial

Mark Lebwohl, Melinda Gooderham, Richard B. Warren, Diamant Thaçi, Peter Foley, Alice B. Gottlieb, Lauren Hippeli, Renata M. Kisa, Subhashis Banerjee, Christopher EM Griffiths

Page s239

PDF

Deucravacitinib in Plaque Psoriasis: 3-Year Safety and Efficacy Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials

April W. Armstrong, Mark Lebwohl, Richard B. Warren, Howard Sofen, Shinichi Imafuku, Mamitaro Ohtsuki, Lynda Spelman, Thierry Passeron, Kim A. Papp, Renata M. Kisa, Victoria Berger, Eleni Vritzali, Kim Hoyt, Matthew J. Colombo, Subhashis Banerjee, Bruce Strober, Diamant Thaçi, Andrew Blauvelt

Page s240

PDF

Deucravacitinib in Plaque Psoriasis: Maintenance of Response Over 3 Years in the Phase 3 POETYK PSO-1 and PSO-2 Trials

Bruce Strober, Howard Sofen, Shinichi Imafuku, Carle Paul, Melinda Gooderham, Lynda Spelman, Seong Jun Seo, Thierry Passeron, Renata M. Kisa, Victoria Berger, Eleni Vritzali, Kim Hoyt, Matthew J. Colombo, Subhashis Banerjee, Matthias Augustin, Linda Stein Gold, Andrew Alexis, Diamant Thaçi, Andrew Blauvelt, Mark Lebwohl

Page s241

PDF

Tapinarof Cream 1% Once Daily Improves Patient-reported Outcomes in the Treatment of Mild to Severe Intertriginous Plaque Psoriasis

Howard Sofen, Stephen Tyring, Sandra Marchese Johnson, Scott Guenthner, Patrick Shannon, Philip M. Brown, Katherine Tillman, Nancy Fitzgerald, Brandon Kirsch, Anna Tallman

Page s242

PDF

Deucravacitinib Long-term Efficacy With Continuous Treatment in Plaque Psoriasis: 2-Year Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials

Diamant Thaçi, Mark Lebwohl, Richard B. Warren, Leon Kircik, Subhashis Banerjee, Andrew Napoli, Renata M. Kisa, Misti Linaberry, Kim Hoyt, Andrew Blauvelt

Page s243

PDF

Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Evaluation of Creatine Phosphokinase Elevations in the Phase 3 POETYK PSO-1 and PSO-2 Trials

Mark Lebwohl, Bruce Strober, Thomas Scharnitz, Misti Linaberry, Kim Hoyt, Subhashis Banerjee, Renata M. Kisa, George Martin

Page s244

PDF

Effect of Subcutaneous Spesolimab on the Prevention of Generalized Pustular Psoriasis Flares Over 48 weeks: Subgroup Analyses from the Effisayil 2 Trial

Richard Warren, David Burden, Siew Eng Choon, Kenneth Gordon, Lluis Puig, Arash Mostaghimi, Georgios Kokolakis, Na Hu, Patrick Hofmann, Christian Thoma, Milan Anadkat

Page s245

PDF

Flare Frequency and Duration in Patients with Generalized Pustular Psoriasis (GPP)

Denis Jullien, Affandi Azura, Laurent Misery, Tang Jyh Jong, Haminda Turki, Pubalan Muniandy, Wooi Chiang Tan

Page s246

PDF

Effect of Spesolimab on Achieving Sustained Disease Remission in Patients with Generalized Pustular Psoriasis: Results from the Effisayil 2 Study

Kenneth Gordon, Curdin Conrad, Mark Lebwohl, Jonathan Barker, Tsen-Fang Tsai, Joseph Merola, Curdin Conrad, Min Zheng, Na Hu, Patrick Hofmann, Christian Thoma, Kilian Eyerich

Page s247

PDF

Real-World Switch Rates for Patients With Psoriasis Initiating Risankizumab Stratified by Body Mass Index

Jashin Wu, Manish Patel, Huzefa Photowala, Chao Li, April Armstrong

Page s248

PDF

Maintenance of Response to Risankizumab in Patients With Psoriatic Arthritis: A 3-year Analysis of the KEEPsAKE 1 and 2 Trials

Andrew Ostor, Michael Chen, Byron Padilla, Cuiyong Yue, Huzefa Photowala, Jonathon Rocco, Joseph Merola

Page s249

PDF

Long-term Safety of Apremilast From a Pooled Analysis of 15 Randomized, Placebo-controlled Studies of Psoriasis, Psoriatic Arthritis, and Oral Ulcers Associated With Behçet’s Syndrome

Philip J. Mease, Gülen Hatemi, Maria Paris, Sue Cheng, Peter Maes, Wendy Zhang, Rebecca Shi, Andrea Flower, Linda Stein Gold; Dawn Nicewarner

Page s250

PDF

Investigator- and Patient-Rated Local Tolerability in Phase 3 Trials of Topical Roflumilast in Patients With Psoriasis, Seborrheic Dermatitis, and Atopic Dermatitis

Christopher Bunick, Neal Bhatia, James Del Rosso, Zoe Draelos, Lawrence Eichnfield, Leon Kircik, Mark Lebwohl, Melinda Gooderham, Lawrence Green, Adelaide Hebert, Ronald Vender, Matthew Zirwas, Eric Simpson, Linda Stein Gold, Melissa Seal, Scott Snyder, David Osborne, Patrick Burnett, Robert Higham, David Chu, David Berk

Page s251

PDF

Roflumilast Cream 0.3% in Patients With Chronic Plaque Psoriasis: Individual Patient Response From the Pooled DERMIS-1 and DERMIS-2 Phase 3 Trials

James Del Rosso, H. Chih-ho Hong, Leon Kircik, Melinda Gooderham, Mark Lebwohl, Kim Papp, Linda Stein Gold, Adelaide Hebert, Melissa Seal, David Krupa, David Chu, Patrick Burnett, David Berk, Robert Higham

Page s252

PDF

How Labeling Warnings and Precautions May Impact the Proportion of Psoriasis Patients Initiating New Treatments

Richard Langley, Shauna Jardon, Jennifer Montgomery, Kate K. Orroth, Cynthia Deignan, Mark Lebwohl; Dawn Nicewarner

Page s253

PDF

Apremilast in Pediatric Patients With Moderate to Severe Plaque Psoriasis: 16-Week Efficacy and Safety Results From the Phase 3, Randomized, Double-Blind, Placebo-Controlled SPROUT Study

Loretta Fiorillo, Emily Becker, Raul de Lucas, Anna Belloni-Fortina, Peter Maes, Rajneet K. Oberoi, Maria Paris, Wendy Zhang, Zuoshun Zhang, Lisa Arkin; Dawn Nicewarner

Page s254

PDF

Efficacy of Apremilast in Patients with Moderate-to-Severe Genital Psoriasis: Body Surface Area Subgroup Results from the Phase 3 DISCREET Trial

Joseph F. Merola, Lawrence Charles Parish, Lyn Guenther, Charles Lynde, Jean-Philippe Lacour, Petra Staubach, Sue Cheng, Cynthia Deignan, Mindy Chen, Kim A. Papp; Dawn Nicewarner

Page s255

PDF

A Phase 3b Study Evaluating Safety and Efficacy of Risankizumab in Adult Patients with Moderate-to-Severe Plaque Psoriasis with Palmoplantar (Non-Pustular) Involvement

Mark Lebwohl, Michael Bukhalo, Linda Stein Gold, Michelle Pelle, Bradley Glick, Mar Llamas-Velasco, Samuel Sanchez-Rivera, Tianyu Zhan, Leonidas Drogaris, Kevin Douglas, Greg St. John, Ramon Espaillat, Robert Bissonnette

Page s256

PDF

Efficacy and Safety of Risankizumab Compared with Apremilast in Patients with Moderate Plaque Psoriasis: Mean PASI and BSA Results From the Phase 4 IMMpulse Trial

Linda Stein Gold, Jerry Bagel, Stephen Keith Tyring, Chih-ho Hong, Lev Pavlovsky, Andreas Pinter, Adam Reich, Leonidas Drogaris, Tianshuang Wu, Huzefa Photowala, Vassilis Stakias, Sven Richter, Kim Papp

Page s257

PDF

Maintenance of Clinical Response With Continued Risankizumab Treatment for Moderate-to-Severe Psoriasis Through 304 Weeks: Interim Analysis of the LIMMitless Open-Label Extension Study

Mark Lebwohl, Hervé Bachelez, Kenneth Gordon, Tianshuang Wu, Michael Chen, Blair Kaplan, Kim Papp

Page s258

PDF

Skin Cancer

Clinical and Histological Clearance of VP-315: Exploratory Results of an Investigational Non-surgical Immunotherapy in Subjects with Biopsy Proven Basal Cell Carcinoma

Neal Bhatia, MD, Jon Kantor, MD, Lawrence Green, MD, Jonathon Weiss, MD, Cynthia Wilson, RN, BSN, Susan Cutler, DMD, Jayson Rieger, PhD, MBA, David K. Glover, ME, PhD, Pamela Rumney, RN, CCRC, Gary Goldenberg, MD

Page s259

PDF

Results from Part 1 Safety Run-in Period of a 2-part, Phase 2, Multicenter, Open-label, Proof-of-Concept Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of VP-315 in Subjects with Basal Cell Carcinoma

Neal Bhatia, MD, Jonathon Kantor, MD, Lawrence Green, MD, Jonathon Weiss, MD, Cynthia Wilson, RN, BSN, Susan Cutler, DMD, Jayson Rieger, PhD, MBA, David K. Glover, ME, PhD, Pamela Rumney, RN, CCRC, Gary Goldenberg, MD

Page s260

PDF

Photodynamic Therapy with 10% Aminolevulinic Acid Gel and Red-Light for the Treatment of Non-Aggressive BCCs: 5-Year Follow-Up Data of a Randomized, Controlled, Comparative, Multicenter Phase-III-Trial

Colin Morton, Rold-Markus Szeimies, Beate Schmitz, Hermann Luebbert

Page s261

PDF

Patient- and Clinician-Reported Outcomes of Tirbanibulin 1% in the Treatment of Actinic Keratosis on the Face and Scalp (PROAK Study)

Todd Schlesinger, April Armstrong, Vishal A. Patel, Leon Kircik, Brian Berman, Neal Bhatia, Mark Lebwohl, Darrell Rigel, Siva Narayanan, Volker Koscielny, Ismail Kasujee, James Del Rosso

Page s262

PDF

Safety and Tolerability of Tirbanibulin 1% Treatment of Actinic Keratosis on Face and Scalp in Routine Clinical Practice Across the U.S. (PROAK Study)

Todd Schlesinger, Mark Lebwohl, James Del Rosso, Vishal A. Patel, Leon Kircik, April Armstrong, Brian Berman, Darrell Rigel, Siva Narayanan, Volker Koscielny, Ismail Kasujee, Neal Bhatia

Page s263

PDF

Safety, Tolerability and Efficacy of Tirbanibulin Ointment 1% Treatment on 100 cm2 of the Face and Scalp in Patients with Actinic Keratosis: A Phase 3 Study

Neal Bhatia, Andrew Blauvelt, Edward Lain, Abel Jarell, Janet DuBois, Maria Luisa Tamarit, Meritxell Falqués, Vera Kiyasova, Laura Padullés, Raquel Otero

Page s264

PDF

Melanoma

Performance of the 23-gene Expression Profile (23-GEP) Test by Histopathological Evaluation in an Independent, Multi-Center Performance Cohort of Cutaneous Melanocytic Neoplasms

Matthew S. Goldberg, Kiran Motaparthi, Gregory A. Hosler, Clay J. Cockerell, Sarah I. Estrada, Natalie D. Depcik-Smith, Jose A. Plaza

Page s265

PDF

Using 31-Gene Expression Profile Testing to Help Guide Adjuvant Therapy and Sentinel Lymph Node Biopsy Discussions with Patients: A Case Series

Peter Prieto

Page s266

PDF

Genomics and Precision Medicine

Gene Expression Differences Identified in Skin Samples of Early-Stage Mycosis Fungoides, Atopic Dermatitis, and Psoriasis

Aaron Farberg, Matthew Goldberg, Ann Quick, Olga Zolochevska, Jeff Wilkinson, Jonathan Silverberg, Peter Lio, John Koo, Jeffrey Weinberg, Mark Lebwohl

Page s267

PDF

Cosmetic

Aesthetic Efficacy of a Novel Topical Combination Brightening Regimen to Treat Facial Hyperpigmentation

Lisa T. Goberdhan, MSHS, Katie Schneider, BS, Arielle Bautista, BS, Elizabeth T. Makino, BS, CCRA, MBA, Rahul C. Mehta, PhD

Page s268

PDF

Red-Light PDT with 10% ALA Gel following Microneedling in the Treatment of Facial AK- Cosmetic and Clinical Outcomes

Dr. Schwartz, Dr. Goldenberg

Page s269

PDF

Atopic Dermatitis

Improvements in Quality of Life and Itch Symptoms with Dupilumab in Patients with Atopic Dermatitis: A Targeted Literature Review and Meta-Analysis of Real-World Studies

Marjolein de Bruin-Weller, Jonathan Silverberg, Debra Sierka, Bruno Martins, Min Yang, Molly Frean, Patricia Guyot, Kerry Noonan, Zhixiao Wang, Gaëlle Bégo-Le-Bagousse

Page s270

PDF

Efficacy and Safety of Lebrikizumab Is Maintained to Two Years in Patients With Moderate-to-Severe Atopic Dermatitis

Emma Guttman-Yassky, Stephan Weidinger, Eric Simpson, Melinda Gooderham, Alan Irvine, Lynda Spelman, Jonathan Silverberg, Hany Elmaraghy, Louise DeLuca-Carter, Maria Lucia Buziqui Piruzeli, Chaoran Hu, Fan Emily Yang, Evangeline Pierce, Laia Bardolet, Diamant Thaci

Page s271

PDF

Lebrikizumab-Treated Patients With Atopic Dermatitis Had No Increase in Treatment-Emergent Adverse Events of Facial, Head, and Neck Erythema Compared to Placebo

Jenny E. Murase, Monica Munera-Campos, H. Chih-ho Hong, Alain Taieb, Wen-Hung Chung, Amber Reck Atwater, Maria Jose Rueda, Jinglin Zhong, Maria Lucia Buziqui Piruzeli, Ignasi Pau-Charles, Mette Deleuran

Page s272

PDF

Lebrikizumab Delivers Clinically Meaningful and Continuous Improvement in Itch-Free Days in Atopic Dermatitis Through One Year

Gil Yosipovitch, Claudia Zeidler, Christian J. Apfelbacher, Vivian Laquer, Brian S. Kim, Marta Casillas, Evangeline Pierce, Sherry Chen, Meihua Qiao, Helena Agell, James Del Rosso

Page s273

PDF

Lebrikizumab Demonstrates Consistent Efficacy at 16 Weeks in Patients With Moderate-to-Severe Atopic Dermatitis Regardless of Baseline Disease Severity

Linda Stein Gold, Kilian Eyerich, Howard Sofen, Pedro Herranz, Leon Kircik, Tony Bewley, Eric Wolf, Gaia Gallo, Yuxin Ding, Fan Emily Yang, Ignasi Pau-Charles, Melinda Gooderham

Page s274

PDF

Patient-Level, Visit-by-Visit Data Highlight the Extent of Skin and Itch Improvement in Atopic Dermatitis With Lebrikizumab

Jonathan Silverberg, Leon Kircik, Melinda Gooderham, Gaia Gallo, Eric Wolf, Helena Agell, Fan Emily Yang, Yuxin Ding, Eric Simpson

Page s275

PDF

Conjunctivitis Does Not Increase With Longer Duration of Lebrikizumab Exposure in Patients With Moderate-to-Severe Atopic Dermatitis

April Armstrong, Andreas Wollenberg, Marjolein de Bruin-Weller, Peter A. Lio, Chitra R. Natalie, Fangyi Zhao, Amber Reck Atwater, Gemma Jimenez, Chia-Yu Chu, Christian Vestergaard

Page s276

PDF

Distribution of SALT scores by Therapeutic Tesponse in Patients with Severe Alopecia After 52 weeks of Baricitinib Therapy

Natasha Atanaskova , Maryanne Senna, Arash Mostaghimi, Julien Seneschal, Amy McMichael, Najwa Somani, Na Lu, Jianxiang Zou, Jakub Jedynak, Hitoe Torisu-Itakura, Jerry Shapiro

Page s277

PDF

Lebrikizumab Provides Progressive Improvements in Skin Clearance and Itch Relief Over One Year in Patients with Atopic Dermatitis

April Armstrong, Kamran Ghoreschi, David Rosmarin, Todd Schlesinger, Alan Irvine, Anthony Bewley, Marta Casillas, Gaia Gallo, Yuxin Ding, Chenjia Xu, Ignasi Pau-Charles, Eric Simpson

Page s278

PDF

Lebrikizumab Provides Rapid Response in EASI Components and Itch in Moderate-to-Severe Atopic Dermatitis

Eric Simpson, Gil Yosipovitch, Kilian Eyerich, Delphine Staumont-Sallé, Mona Shahriari, Gaia Gallo, Eric Wolf, Evangeline Pierce, Chunyuan Liu, Jinglin Zhong, Helena Agell, Marjolein de Bruin-Weller

Page s279

PDF

Tapinarof Cream 1% Once Daily for the Treatment of Extensive Atopic Dermatitis in Adolescents and Children: Outcomes from the 4-Week Maximal Usage Trial

Amy Paller, Adelaide A. Hebert, Philip M. Brown, Victoria Butners, Nancy Fitzgerald, Mercedes E. Gonzalez, Stephen C. Piscitelli

Page s280

PDF

Rapid and Early Onset of Itch Relief with Tapinarof Cream 1% Once Daily in Two Pivotal Phase 3 Trials in Adults and Children Down to Two Years of Age with Atopic Dermatitis

Eric Simpson, Jonathan I. Silverberg, Robert Bissonnette, Linda Stein Gold, April Armstrong, Adelaide A. Hebert, Rocco T. Serrao, Jeannette R. Jakus, Philip M. Brown, David S. Rubenstein, Stephen C. Piscitelli, Anna Tallman, Lawrence F. Eichenfield

Page s281

PDF

Lebrikizumab Provides Stable Itch Response With No or Minimal Fluctuations up to One Year in Patients With Atopic Dermatitis

James Del Rosso, Gil Yosipovitch, Sonja Ständer, Jonathan Silverberg, Andreas Wollenberg, Peter A. Lio, Jose Manuel Carrascosa, Gaia Gallo, Marta Casillas, Evangeline Pierce, Yuxin Ding, Zhenhui Xu, Helena Agell, Linda Stein Gold

Page s282

PDF

Tapinarof Cream 1% Once Daily: Significant Efficacy in the Treatment of Atopic Dermatitis in Two Pivotal Phase 3 Trials in Adults and Children Down to 2 Years of Age

Jonathan I. Silverberg, Lawrence F. Eichenfield, Adelaide A. Hebert, Eric Simpson, Linda Stein Gold, Robert Bissonnette, Kim A. Papp, John Browning, Pearl Kwong, Neil J. Korman, Philip M. Brown, David S. Rubenstein, Stephen C. Piscitelli, Matthew C. Somerville, Anna Tallman, Leon Kircik

Page s283

PDF

Patient Preferences in Moderate-to-Severe Atopic Dermatitis (AD): A Discrete Choice Experiment (DCE)

Steven R. Feldman, Annie Guerin, Marjolaine Gauthier-Loiselle, Ami J Claxton, Nisha C Hazra, Yan Meng, Kirsten Gallant, Sanjeev Balu

Page s284

PDF

Clinical Burden and Impairment in Moderate-to-Severe Atopic Dermatitis

Nisha Hazra, Steven R. Feldman, Annie Guerin, Marjolaine Gauthier-Loiselle, Ami J Claxton, Yan Meng, Kirsten Gallant, Sanjeev Balu

Page s285

PDF

Hidradenitis Suppurativa

Spesolimab for Hidradenitis Suppurativa: A Proof-of-Concept Study

Afsaneh Alavi, Errol Prens, Alexa Kimball, James Krueger, Sutirtha Mukhopadhyay, Hui Wang, Nathalie Ivanhoff, Ana Cristina Hernandez, Christos Zouboulis

Page s286

PDF

Miscellaneous

Treatment of Patient with Cutaneous Lupus Erythematosus with Roflumilast Cream 0.3%

Morgan McCarty

Page s287

PDF

Seasonal and Geographical Trends in Photodynamic Therapy and Cryosurgery Utilization in the United States: A Cross=Sectional Study from 2015-2022

Dr. Dawn Merritt, Dr. Jon Lyons, Dr. Mouna Mikati, Dr. Todd Schlesinger

Page s288

PDF

Alopecia

Integrated Safety Analysis of Ritlecitinib for the Treatment of Alopecia Areata (AA) From the Phase 2 and Phase 3 ALLEGRO Clinical Trial Program

Brett King, Jennifer Soung, Christos Tziotzios, Lidia Rudnicka, Pascal Joly, Melinda Gooderham, Rodney Sinclair, Susan D. Anway, Dalia Wajsbrot, Alexandre Lejeune, Samuel H. Zwillich

Page s291

PDF

Impact of Previous Alopecia Areata Treatment on Efficacy Responses After 24 and 48 Weeks of Treatment With Ritlecitinib

Jennifer Fu, Alexander Egeberg, Susan Holmes, Sergio Vano-Galvan, Martin Steinhoff, Roger Edwards, Ranjit Nagra, Robert Wolk, Helen Tran, Ernest Law

Page s292

PDF

Sustained Scalp, Eyebrow, and Eyelash Hair Regrowth with Ritlecitinib Through Week 48 in Patients with Alopecia Areata: Post-Hoc Analysis of the ALLEGRO Phase 2b/3 Study

Melissa Piliang, Charles Lynde, Brett King, Paradi Mirmirani, Rodney Sinclair, Robert Wolk, Samuel Zwillich, Helen Tran, Fan Zhang, Liza Takiya

Page s293

PDF

Integrated Safety Analysis of Ritlecitinib in Adolescent Patients with Alopecia Areata from the Randomized, Placebo-Controlled ALLEGRO Phase 2b/3 and Ongoing Open-Label Phase 3 ALLEGRO-LT Studies

Jennifer Soung, Brett King, Christos Tziotzios, Lidia Rudnicka, Pascal Joly, Melinda Gooderham, Rodney Sinclair, Dalia Wajsbrot, Helen Tran, Robert Wolk

Page s294

PDF

Agreement Between Patient and Physician Assessment of Eyebrow and Eyelash Hair Loss in Two Phase 3 Trials Evaluating Baricitinib in Patients with Severe Alopecia Areata

Justin Ko, Amy McMichael, Antonella Tosti, Taisuke Ito, Yves Dutronc, Guanglei Yu, Yunfei Chen, Mwangi Murage, Chiara Chiasserini, Arash Mostaghimi

Page s295

PDF

Outcomes of Down-Titration in Patients With Severe Scalp Alopecia Areata Treated With Baricitinib: An Update Through Week 152 From BRAVE-AA2

Brett King, Manabu Ohyama, Maryanne Senna, Jerry Shapiro, Yves Dutronc, Jill Kolodsick, Guanglei Yu, Chunyuan Liu, Chiara Chiasserini, Bianca Maria Piraccini

Page s296

PDF

Baricitinib Treatment Increases Eyebrow and Eyelash Regrowth Up to 52 Weeks

Arash Mostaghimi, Melissa Piliang, Charles Lynde, Jacek C. Szepietowski, Jakub P. Jedynak, Najwa Somani, Na Lu, Guanglei Yu, Chiara Chiasserini, Maria Hordinsky

Page s297

PDF

Pruritus & Prurigo Nodularis

Anxiety and Depression in Patients with Prurigo Nodularis: Results from the PN – Patient Reported Burden of Sickness (PN-TREK) Study

Shawn G Kwatra, Bruno Martins, Min Yang, Abigail Zion, Joseph Zahn, Bengisu Ozarslan, Donia Bahloul, Ryan B Thomas

Page s298

PDF

Acne & Rosacea

Comparative Bioavailability of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) Vs. Minocycline Hydrochloride Extended Release 105-mg tablets After a Single Oral Dose: A Randomized, 3-way Crossover Study

Dr. Srinivas Sidgiddi, Aniruddh Gautam, MPharm

Page s289

PDF

A Systematic Literature Review and Network Meta-Analysis of Comparative Efficacy of Topical Fixed-Dose Combination Treatments for Moderate to Severe Acne Vulgaris

Julie C Harper, Hilary E Baldwin, Saswata Paul Choudhury, Bikramaditya Ghosh, Deepti Rai, Md Sohail Aman, Abhra Roy Choudhury, Debalina Dey , Sekhar K Dutta, Subrata Bhattacharyya, Tina Lin, George Joseph, Ankur A Dashputre, Jerry Tan

Page s290

PDF

Urticaria

Comparison of Study Designs for Primary Phase III Trials for Omalizumab Versus Dupilumab for Patients With Chronic Spontaneous Urticaria

Andrew Alexis, Kyle Anders, Arpamas Seetasith, Michael Holden

Page s299

PDF

Psoriasis

Bimekizumab in Patients with Moderate to Severe Plaque Psoriasis: Analysis of Mental Health and Associated Disorders

Andrew Blauvelt, April Armstrong, Joseph F. Merola, Bruce Strober, Dirk de Cuyper, Luke Peterson, Owen Davies, Jeffrey L. Stark, Mark Lebwohl

Page s300

PDF